4/26
12:00 pm
supn
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
4/24
04:05 pm
supn
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Medium
Report
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
4/24
03:17 pm
supn
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
4/20
11:00 am
supn
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
4/18
11:30 am
supn
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
4/8
12:20 pm
supn
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease [Yahoo! Finance]
Low
Report
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease [Yahoo! Finance]
4/8
08:14 am
supn
Supernus Provides Regulatory Update for SPN-830 [Yahoo! Finance]
Medium
Report
Supernus Provides Regulatory Update for SPN-830 [Yahoo! Finance]
4/8
08:00 am
supn
Supernus Provides Regulatory Update for SPN-830
Low
Report
Supernus Provides Regulatory Update for SPN-830
4/8
07:18 am
supn
Data from Newron's study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) [Yahoo! Finance]
Medium
Report
Data from Newron's study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) [Yahoo! Finance]
3/19
07:06 am
supn
Newron Presents 2023 Financial Results and Provides 2024 Outlook [Yahoo! Finance]
Low
Report
Newron Presents 2023 Financial Results and Provides 2024 Outlook [Yahoo! Finance]
3/15
07:16 am
supn
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement [Yahoo! Finance]
Low
Report
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement [Yahoo! Finance]
3/13
02:43 pm
supn
Dr. Vince Clinical Research Announces First Dosing in a Phase II Study in Patients With Depression [Yahoo! Finance]
Low
Report
Dr. Vince Clinical Research Announces First Dosing in a Phase II Study in Patients With Depression [Yahoo! Finance]
3/6
04:36 pm
supn
Supernus to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Supernus to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]
3/6
04:30 pm
supn
Supernus to Participate in Two Upcoming Investor Conferences
Low
Report
Supernus to Participate in Two Upcoming Investor Conferences
3/4
12:11 pm
supn
Supernus Pharmaceuticals: Moving Through An 'Inflection Year' [Seeking Alpha]
Low
Report
Supernus Pharmaceuticals: Moving Through An 'Inflection Year' [Seeking Alpha]
2/28
04:46 pm
supn
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference [Yahoo! Finance]
2/28
04:30 pm
supn
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
Medium
Report
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
2/28
10:57 am
supn
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) had its price target lowered by analysts at Piper Sandler from $45.00 to $41.00. They now have an "overweight" rating on the stock.
Medium
Report
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) had its price target lowered by analysts at Piper Sandler from $45.00 to $41.00. They now have an "overweight" rating on the stock.
2/28
09:33 am
supn
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Neutral
Report
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/27
09:17 pm
supn
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
Medium
Report
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
2/27
08:25 pm
supn
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates [Yahoo! Finance]
Medium
Report
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates [Yahoo! Finance]
2/27
05:09 pm
supn
Supernus Pharmaceuticals Inc (SUPN) Reports Robust Growth in Key Products for Full Year 2023 [Yahoo! Finance]
Medium
Report
Supernus Pharmaceuticals Inc (SUPN) Reports Robust Growth in Key Products for Full Year 2023 [Yahoo! Finance]
2/27
04:23 pm
supn
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
2/27
04:05 pm
supn
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
Low
Report
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
2/26
11:03 am
supn
Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics [Yahoo! Finance]
Low
Report
Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics [Yahoo! Finance]